Compugen Ltd., a clinical-stage cancer immunotherapy company using AI/ML for drug discovery, announced its management will participate in an AI/ML-based drug development discussion on June 15, 2026. The company is advancing several clinical-stage cancer treatments, including COM701 and COM902 for solid tumors, and rilvegostomig, developed with AstraZeneca, currently in multiple clinical trials. Compugen's innovative pipeline highlights its focus on novel immuno-oncology therapies, with ongoing trials such as the MAIA-ovarian trial for ovarian cancer. This event and the company's progress underscore its role in pioneering AI-driven cancer therapies.
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ERock, Inc. received a buy rating due to its innovative modular natural-gas power systems that help data centers avoid long waits for permanent grid power. The company has a strong $1.3 billion backlog supported by customer deposits, providing clear ...
IBM's business model remains strong despite a 7% decline in mainframe infrastructure revenue, supported by loyal legacy customers and solid free cash flow. Software growth, especially an 11% increase in Red Hat revenue, helps offset mainframe challen...
